Information Provided By:
Fly News Breaks for June 8, 2017
RHHBY, NLNK
Jun 8, 2017 | 09:26 EDT
Cantor Fitzgerald analyst Mara Goldstein says that while Roche's (RHHBY) decision to return the rights to GDC-091 is disappointing, the broader research collaboration with NewLink Genetics (NLNK) on next-generation IDO compounds remains intact. The analyst notes that her $32 price target for NewLink is under review. Goldstein expects further clarity around the future of GDC-091 as NewLink begins evaluation later this year. The analyst has an Overweight rating on the shares.
News For NLNK;RHHBY From the Last 2 Days
RHHBY
RHHBY
RHHBY
Apr 24, 2024 | 06:30 EDT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.